The memoinOncology initiative

What is memoinOncology?

 

Time constraints prevent HCPs from attending all relevant congresses and meetings relevant to their practice. In addition, COVID-19 has prevented physical meetings and congress attendance for the past year.

 

memoinOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications.

 

Resources are offered in various formats, in English, Mandarin and Japanese, and are distributed via diversified distribution channels in order to keep HCPs informed of the latest developments in their field – at their convenience and without the need for travel or incurring any costs. 

 

Collaborations with multiple international oncology and hematology societies such as the Chinese Society of Clinical Oncology (CSCO), the Latin American Cooperative Oncology Group (LACOG), the Sociedad Ecuatoriana de Oncología (SEO – Ecuadorian Oncology Society) and the Singapore Society of Oncology (SSO) allows memoinOncology to distribute these resources widely around the globe.

 

Unrestricted medical education grants from multiple sponsors  allow us to cover a wide variety of indication and therapy areas, remaining unbiased and focused on providing high quality medical education resources.

 

What does memoinOncology offer?

 

The memoinOncology platform provides research and congress highlights as high value medical education for HCPs and societies, which ultimately benefits patients. Resources on offer include:

  • Congress reports written and released within weeks of major congresses such as ESMO, ASCO, EHA, ASH and more. These reports bring key findings from several carefully selected abstracts from each congress, with a focus on particular indications and therapy areas. They are free to view and download as PDFs. Recent examples include:
  • Slide kits accompany each congress report, providing a condensed and highly visual summary of select abstracts from the congress reports with a specific focus on therapy areas of special interest. They are free to view and download as PowerPoints. Recent examples include:
  • Expert video interviews provide world expert insights into the relevance of new trial data to the current treatment paradigm, emerging therapies and practice guidelines. In our exclusive video interviews experts explore specific aspects of recent trials in various indications, and the implications of the results for clinical practice and patient outcomes. They are free to view online. Recent examples from ESMO 2020 include:
      • Andrés Cervantes discusses novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.
      • Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.
    • Preceptorship reports summarize the latest in cancer and hematology research and treatments emerging from our preceptorship meeting series. Sponsored with unrestricted medical education grants, Springer preceptorship meetings bring specialists from around the world to a centre of excellence, where experts present the latest hot topics.
    • Optional newsletters allow users to register to receive updates on the latest memoinOncology publication

 

Why does BeiGene support memoinOncology?

Our motto is ‘Cancer has no borders – and neither do we’, and we feel that memoinOncology shares our passion for supporting doctors around the world provide the very best in patient care.

 

Our mission is to make the highest quality therapies available to billions more people — through courage, persistent innovation, and challenging the status quo. We believe that providing HCPs with a means to access unbiased, up-to-date information from the very latest developments and clinical trials benefits HCPs and patients alike, and we are happy to support the memoinOncology initiative with this in mind.

Slide Kit PD-1/PD-L1 and PARP inhibition in NSCLC

 

Slidekit BTK inhibition in B-Cell Malignancies

 

Constantine Tam depicts the most interesting trial results in the field of CLL treatment at the EHA congress and gives an outlook on future treatment options for CLL and mantle cell lymphoma.

 

Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety, next-generation BTK inhibitors and recent developments in the management of cold agglutinin disease.

 

Veronique Leblond highlights relevant factors for the selection of treatment in newly diagnosed and relapsed Waldenström’s macroglobulinemia, the connection of BTK inhibitors and MYD88 or CXCR4 mutations and discusses the risk-benefit profile of these drugs.

 

Peter Hillmen gives an overview of the most relevant treatment strategies in ­patients with paroxysmal nocturnal hemoglobinuria and further explains the advantages of proximal over terminal complement inhibition.

 

memo - inOncology SPECIAL ISSUE - ESMO 2020